Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="19914246" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="keywords" meta.keywordsubtype="org" meta.entityname="Zydus Lifesciences" meta.hostid="261" meta.entityid="Zydus Lifesciences">Zydus Lifesciences</keyword> on Friday said its consolidated <keyword id="19942166" type="General" weightage="20" keywordseo="net-profit" source="keywords">net profit</keyword> surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal. Revenue from operations rose to Rs 5,534 crore in the period under review from Rs 5,011 crore in the year-ago period, Zydus Lifesciences said in a statement. For the year ended March 31, 2024, the company reported a consolidated net profit of Rs 3,859 crore as compared with Rs 1,960 crore in FY23. Revenue from operations rose to Rs 19,547 crore from Rs 17,237 crore in the 2022-23 fiscal. "Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well," Zydus Lifesciences MD Sharvil Patel said. The company said its board has approved a final dividend of Rs 3 per equity share of Re 1 each, subject to approval of the shareholders. Shares of the company ended 4.28 per cent up at Rs 1,051.90 apiece on the BSE. SEE ALSO:<a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank">Motorola Edge 50 Fusion vs OnePlus Nord CE 4 – price, specs and features compared</a><a href="https://www.businessinsider.in/india/news/average-housing-prices-up-10-in-jan-mar-across-the-top-eight-cities/articleshow/110181627.cms" target="_blank"></a> <a href="https://www.businessinsider.in/india/news/average-housing-prices-up-10-in-jan-mar-across-the-top-eight-cities/articleshow/110181627.cms" target="_blank">Average housing prices up 10% in Jan-Mar across the top eight cities</a><a href="https://www.businessinsider.in/tech/mobile/news/motorola-edge-50-fusion-with-144hz-poled-display-500mah-battery-launched-starting-at-22999/articleshow/110170762.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/news/motorola-edge-50-fusion-with-144hz-poled-display-500mah-battery-launched-starting-at-22999/articleshow/110170762.cms" target="_blank">Motorola Edge 50 Fusion with 144Hz pOLED display, 5,00mAh battery launched starting at ₹22,999</a>

Zydus Q4 net profit surges 4-fold to ₹1,182 cr; revenue at ₹5,534 cr

New Delhi, <keyword id="13247465" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="Orion">Zydus Lifesciences</keyword> on Tuesday said it has acquired UK-based LiqMeds Group for GBP 68 million (around Rs 689 crore). The Ahmedabad-based group, through its wholly-owned subsidiary Zydus Pharmaceuticals UK Ltd, will also pay yearly earn-outs until 2026 depending on the achievement of certain agreed milestones towards the acquisition. LiqMeds Group of companies specialises in the development, manufacturing and supply of oral liquid products for global markets. The group's subsidiary LM Manufacturing Ltd has an oral liquids manufacturing site at Weedon, Northampton, UK, which supplies products to the US and UK markets. "Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on the achievement of certain agreed milestones towards the acquisition of the LiqMeds Group of companies," the company said in a regulatory filing. The transaction will be EPS accretive for Zydus from the first year of acquisition, it added. "We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities," Zydus Lifesciences Managing Director Sharvil Patel said. In line with the patient-centric approach, the company believes that oral liquid formulations would help geriatric and paediatric patients, bringing in greater ease of convenience and therapy compliance, he added. Shares of Zydus were trading at 0.89 per cent lower at Rs 574.70 apiece on the BSE.

Zydus Lifesciences acquires UK-based LiqMeds Group for GBP 68 million

New Delhi, <keyword id="13247465" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="Orion">Zydus Lifesciences</keyword> Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 1,086.9 crore for the first quarter ended June 30, 2023 driven by strong sales growth from US formulations. The company had posted a net profit of Rs 518.3 crore for the same quarter last fiscal, Zydus Lifesciences said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 5,139.6 crore as against Rs 3,964.4 crore in the year-ago period, up 29.6 per cent. India geography clocked sales of Rs 1,920.6 crore in the first quarter as compared to Rs 1,816.7 crore in the corresponding period a year ago. Sales from US formulations were at Rs 2,454.1 crore as compared to Rs 1,559.2 crore in the same quarter a year ago, up 57.4 per cent, the company said. Active pharmaceutical ingredients clocked sales of Rs 138.9 crore in the first quarter as against Rs 122.4 crore in the corresponding quarter last fiscal, it added. During the quarter, the company witnessed a broad-based operational growth in its key businesses and a favourable product mix enhanced profitability, Zydus Lifesciences Managing Director Sharvil Patel said. "Strong execution and volume offtake drove revenue ramp-up in the US, while the India branded formulations business, adjusting for NLEM (national list of essential medicines) impact delivered solid 12 per cent growth," he added. On the outlook, he said,"We remain reassured on achieving profitable growth aspirations for the fiscal year and thereby enhance stakeholder value."

Zydus Lifesciences Q1 2023-24 profit up 2-fold at Rs 1,087 cr

Surpassing its domestic and global peers, Cadila Healthcare has come up as the frontrunner to acquire the generic sterile injectables business of Ahmedabad-headquartered <keyword id="356962" type="COMPANY" weightage="80" keywordseo="Claris-Lifesciences-Ltd">Claris Lifesciences Ltd</keyword> (CLL). 
 
As per sources, the last minutes negotiations are underway between the both companies, including tax and other financial matters. A formal announcement is expected next month as the deal has not yet closed. 
 Cadila Healthcare, the <keyword id="270579" type="COMPANY" weightage="80" keywordseo="Zydus-Cadila-Group">Zydus Cadila Group</keyword> flagship, is likely to pay a significant premium, valuing the company between Rs 3,100 crore - Rs 3,400 crore. 
 
For 12 months ending December 31, 2014, Claris Lifesciences business reported revenues of Rs 405.6 crore and EBITDA of Rs 149.4 crore (37% EBITDA margin). 
 
Presently, the market cap of parent Claris Lifesciences including all the different businesses is Rs 1,793 crore. 
 
The Cadila Healthcare spokesperson told ET, as a matter of policy, the company does not comment on market speculation. A Claris spokesperson however denied any such development. 
 
Economic Times in February first reported about the business being put on the block. 
 
The financial daily reported the possible deal underscores amplified interest in the business in the backdrop of a global shortage of injectables -- drugs that are delivered through vials, syringes and bags, as well as pumps. The supply problems have driven many transactions both in India and overseas, including Pfizer's $17 billion takeover of Hospira, earlier this year. 
 
Pankaj Patel-led Cadila had competition from domestic rivals like Lupin who were also pursuing the opportunity to buy the asset, but valuations apart, comfort between the two Gujarat based entrepreneurs is said to have provided extra comfort to Arjun Handa, the promoter, vice-chairman &amp; managing director of CLL. 
 
ET reported both Patel and Handa are from Ahmedabad and have been old industry associates. Even global players like Pfizer, Amneal and Novartis, among others, were initially in the fray, added sources. 
 
One of the sources told ET, if talks with Cadila breaks down at the wire then the prospects of Lupin, another potential contender, to walk away with the asset could improve considerably. 
 
Cadila, among the top five pharmaceuticals companies in the country in terms of revenues --- these amounted to Rs 8,651 crore for year ended 31 March 2015 ---has been acquisitive for a while having executed 17 M&amp;A deals since 1995. 
 
(Image: Indiatimes)

Cadila Healthcare trumps peers, in talks to acquire Claris Lifesciences for whooping Rs 3,400 crore

<ul><li>Dr. Reddy’s Laboratories <a href="https://timesofindia.indiatimes.com/business/india-business/dr-reddys-launches-remdesivir-to-treat-covid-19-in-india/articleshow/78015814.cms">launched</a> generic drug <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">Remdesivir</keyword> under the brand name Redyx in India on September 9. </li><li>Redyx will be available in the market for ₹5,400 per 100 mg vial. </li><li><keyword id="72130" type="COMPANY" weightage="20" keywordseo="Zydus-Cadila">Zydus Cadila</keyword>, on August 13, launched the cheapest version of Remdesivir under the brand name Remdac. </li><li>Apart from <keyword id="6357157" type="UNKNOWN" weightage="20" keywordseo="cipla">Cipla</keyword> and <keyword id="1167725" type="PERSON" weightage="20" keywordseo="Hetero-Labs">Hetero Labs</keyword>, Jubilant Lifesciences and Mylan are working to manufacture the drug in India. </li></ul>Dr Reddy’s Laboratories has <a href="https://timesofindia.indiatimes.com/business/india-business/dr-reddys-launches-remdesivir-to-treat-covid-19-in-india/articleshow/78015814.cms">launched</a> the generic drug Remdesivir under the brand name Redyx in India. Remdesivir used to treat patients suffering from severe symptoms of COVID-19. Redyx will be available in the market for ₹5,400 per 100 mg vials. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdesivir Price </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero Labs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5000-₹6000 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Redyx </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5400 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹4000</td></tr></tbody></table> Dr Reddy’s Lab is the sixth pharmaceutical company to introduce Remdesivir in India. On August 13, Zydus Cadila launched its own version of Remdesivir called Remda in the Indian market. Remdac is priced at ₹2,800 per 100 mg vial, making it the cheapest version of the drug so far. Zydus Cadila said that the drug will be made available across India through the group's strong distribution chain reaching out to government and private hospitals treating COVID-19 patients. In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational drug, which has been issued an emergency use authorisation by the US Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of COVID-19. Previously, pharmaceutical giants Cipla and Hetero introduced generic versions Remdesivir — an antiviral drug first used to treat Ebola — to fight coronavirus. The drug was launched in India in July. India’s Health Ministry approved use of the drug to treat mild cases of coronavirus. However, the drug is not recommended to treat those who have several renal impairment, pregnant and lactating women, children below 12 years age. Hetero said it will make its version of Remdesivir — Covifor — available between ₹5,000 to ₹6,000 for a vial. Whereas, Cipla's Cipremi is available for ₹4000 for per 100 mg vial. Cipla’s Cipremi is available for only those patients who are on oxygen support. Apart from Cipla and Hetero Labs, Jubilant Lifesciences and Mylan are also working to manufacture the drug in India. Dr Reddy’s Laboratories, Biocon firm Syngene and has also received voluntary permission from Gilead Sciences to produce Remdesivir in India. (With inputs from PTI) SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/why-the-latest-surge-in-covid-19-infections-in-india-may-cause-more-deaths/articleshow/78011731.cms">What India’s rising COVID-19 infections don’t⁠ reveal — the lack of health infrastructure in remote areas</a>

These are the companies that are making Remdesivir in India

<ul><li>Zydus Cadila, on August 13, launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19. </li><li>Priced at ₹2,800 per 100 mg vial, it is the cheapest <keyword id="9013152" type="UNKNOWN" weightage="20" keywordseo="remdesivir-drug">Remdesivir drug</keyword> available in India </li><li>Apart from Cipla and Hetero Labs, Jubilant Lifesciences, and Mylan are working to manufacture the drug in India. </li></ul>Zydus Cadila has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market. Remdac is priced at ₹2,800 per 100 mg vial, making it the cheapest version of the drug so far. Zydus Cadila is the fifth company to make this antiviral drug in India. They have said that the drug will be made available across India through the group's strong distribution chain reaching out to government and private hospitals treating COVID-19 patients. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdesivir Price </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero Labs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5000-₹6000 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Not disclosed yet </td></tr></tbody></table> In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational drug, which has been issued an emergency use authorisation by the US Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of COVID-19. Previously, pharmaceutical giants Cipla and Hetero introduced generic versions Remdesivir — an antiviral drug first used to treat Ebola — to fight coronavirus. India’s Health Ministry approved use of the drug to treat mild cases of coronavirus. However, the drug is not recommended to treat those who have several renal impairment, pregnant and lactating women, children below 12 years age. Hetero said it will make its version of Remdesivir — Covifor — available between ₹5,000 to ₹6,000 for a vial. Whereas, Cipla is yet to decide the cost of Cipremi. Cipla’s Cipremi is available for only those patients who are on oxygen support. Apart from Cipla and Hetero Labs, Jubilant Lifesciences and Mylan are also working to manufacture the drug in India. Dr Reddy’s Laboratories, Biocon firm Syngene and has also received voluntary permission from Gilead Sciences to produce Remdesivir in India. (With inputs from PTI) SEE ALSO: <a href="https://www.businessinsider.in/politics/world/news/trump-was-rushed-from-the-briefing-room-by-secret-service-after-a-shooting-outside-of-the-white-house/articleshow/77474005.cms">Trump was rushed from the briefing room by Secret Service after a shooting outside the White House</a> <a href="https://www.businessinsider.in/careers/news/mckinsey-facebook-amazon-nokia-and-some-other-companies-looking-for-a-product-manager-right-now/slidelist/77464438.cms">McKinsey, Facebook, Amazon, Nokia — and some other companies looking for a product manager right now</a> <a href="https://www.businessinsider.in/business/startups/news/how-karan-bajaj-sold-his-less-than-18-month-old-startup-white-hat-jr-to-byjus/articleshow/77415329.cms">A WhatsApp message, six weeks of talks and a $300 million deal – how Karan Bajaj sold his less than 18-month old startup White Hat Jr to Byju’s</a>

Drug maker Cipla Limited on Sunday announced the launch of experimental anti-viral drug remdesivir under its <keyword id="9441113" type="UNKNOWN" weightage="20" keywordseo="brand-name-cipremi">brand name Cipremi</keyword>. Remdesivir is the only US FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, US drug maker Gilead Sciences extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla's generic version of remedisvir called Cipremi. The Drug Controller General of India (DCGI) has granted Cipla regulatory approval for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need, the company said in a statement. As part of a risk management plan, Cipla will provide training on use of the drug, inform patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV <keyword id="122283" type="PERSON" weightage="20" keywordseo="Clinical-trial">clinical trial</keyword> on Indian patients. "Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by Covid-19 pandemic, and this launch is a significant milestone in that direction," said Umang Vohra MD and Global CEO, Cipla. According to a preliminary report from the ACTT-1 (Adaptive COVID-19 Treatment Trial 1) study, a randomized clinical trial conducted with remdesivir on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. Most of these patients were on oxygen therapy of which some were receiving high flow oxygen or non-invasive ventilation, and some were on a mechanical ventilator. The mortality rates in the study were 7.1 per cent in those given remdesivir and 11.9 per cent in those who were given placebo. In May, Gilead Sciences signed non-exclusive voluntary licensing agreements with six Indian pharmaceutical companies to boost the supply of remdesivir, the experimental antiviral drug that has shown promise in Covid-19 treatment. These companies were -- Dr. Reddy's Laboratories Ltd., <keyword id="9441116" type="COMPANY" weightage="20" keywordseo="zydus-cadila-healthcare-ltd-">Zydus Cadila Healthcare Ltd.</keyword>, Biocon company Syngene, Hetero Labs Ltd.; Jubilant Lifesciences; and Cipla Ltd. Media reports said that Hetero Labs Ltd has also received regulatory approval from DCGI but the drug maker was yet to make it official. Cipla said it will be commercialising remdesivir through its own facilities and partnered sites. The drug will be supplied through government and open market channels, to ensure equitable distribution. SEE ALSO: <a href="https://www.businessinsider.in/india/news/water-sold-in-aluminum-cans-to-avoid-plastic-use-is-the-latest-trend-in-india/articleshow/76490551.cms" data-type="tilCustomLink">Water sold in aluminum cans to avoid plastic use is the latest trend in India – but costs six times than that of a mineral water bottle</a> <a href="https://www.businessinsider.in/tech/news/can-non-chinese-mobile-brands-leverage-current-consumer-sentiment-in-india/articleshow/76490835.cms" data-type="tilCustomLink">Can non-Chinese mobile brands leverage current consumer sentiment in India?</a>

Cipla to sell anti-viral drug remdesivir as Cipremi in India

<ul><li><keyword id="4764339" type="General" weightage="20" keywordseo="drug-shortages" source="Orion">Drug shortages</keyword>, channel realignment and woes of competitors to aid US business of <keyword id="58106" type="General" weightage="20" keywordseo="indian-pharma" source="Orion">Indian pharma</keyword> cos.</li><li>Dr Reddy’s, Cipla, Zydus and Sun Pharmaceuticals gained from sales of generic cancer drugs in the US.</li><li>US FDA inspections are in full swing and the accelerating pace of new launches will improve outlook for US business in FY24, say analysts. </li></ul>The Indian pharma sector has gone through many ups and downs in the last few years – like falling from a Covid-high last year, adding to pricing pressures in its most important market. In the first quarter of FY24 however some of the US market pricing pressures are easing, making up for the slump in domestic sales. “Q1 FY24 turned out to be a tale of two divergent performances as US delivered across the board beat while domestic business, specifically acute, saw weakness in June. Price erosion came in at high single digit in US versus mid-teens last year reflecting in better US revenue growth and profitability,” said a report by YES Securities. Drug shortages, channel realignment and financial as well as regulatory woes of competitors seems to have helped curb US market price erosion in Q1 on a quarter-on-quarter, say analysts. The US market has been dented in the last few years for many reasons including pricing pressures — like supply chain disruptions, and a massive delay in approval of Abbreviated New Drug Applications (ANDAs) leading to fewer generic launches in the US. However, the ability to launch the generic version of a cancer drug gRevlimid in the US abated some of the concerns. Dr Reddy’s generated sales to the tune of $125 million from this generic in Q1 while Cipla, Zydus and Sun Pharmaceuticals reported gRevlimid sales between 40-60 million. “We believe the earnings support from gRevlimid is expected to drive the US base business and abate pricing pressure for the coming two years. Moreover, US FDA inspections are in full swing and the accelerating pace of new launches will improve outlook for US business in FY24,” J M Financial. Lupin and Zydus Life benefitted from exclusive launches of gSuprep and gTrokendi. Darunavir and gSpiriva are other drugs in the pipeline that can boost North America sales of Indian pharma companies. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stock </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Growth levers ahead </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sun Pharma </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Specialty performance </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddys </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revlimid contribution to sustain in 2Q </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Lifesciences </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Near-term US outlook promising </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">US base biz at $210- 215 mn hereon: mgmt </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Lupin </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Attractive launch pipeline </td></tr></tbody><tbody></tbody><tbody></tbody></table>Source: J M Financial Sun shines in the <keyword id="6382118" type="General" weightage="20" keywordseo="domestic-market" source="Orion">domestic market</keyword> The domestic <keyword id="101756" type="General" weightage="20" keywordseo="pharma-market" source="Orion">pharma market</keyword> seems to see the after-effects of a delayed monsoon, which led to weakness in acute therapies like gastroenteritis which aids seasonal sales in Q1. This trend impacted key players like Dr Reddy’s, JB Chemicals and Alkem. Alkem however said that there has been no change in domestic sales even in July, August is expected to provide some quality on the same. Sun Pharma, however, is an outlier with a good performance in the domestic business as it boosted its sales strength along with new launches. It launched 105 new products in FY23 as compared to 77 new launches the year before. “Sun’s India business has grown at 11% compounded annual growth rate (CAGR) over FY20-23, driven by volume, price and new launches. We expect Sun’s India business to grow at around 10% CAGR over FY23-26,” said a report by IIFL Securities. <div type="javascript" title="Custom" contenttype="Text"><cdata><![CDATA[]]></cdata></div>

US outlook improves for Indian pharma but domestic market under the cloud

<ul><li>Remdesivir has little or no effect on hospitalised COVID-19 patients, according to a new study by the World Health Organisation (WHO).</li><li>When coronavirus pandemic initially broke, it emerged as one of the most preferred treatments for the disease around the world.</li><li>In July, Gilead released further data suggesting that Remdesivir <a href="https://www.ft.com/content/978b4f8a-62b5-43a0-ad32-dda1930ec47c">may improve chances of survival among COVID-19 patients.</a> However, these findings were not confirmed by a randomised controlled trial until now. </li><li>Even before WHO’s study, a Lancet report <a href="https://www.businessinsider.in/science/health/news/remdesivir-the-coronavirus-miracle-drug-may-be-overhyped-suggests-lancet-study/articleshow/75470476.cms">contradicted </a>Gilead’s claims indicating that the drug may not be the most ‘promising’ treatment for coronavirus.</li><li>Not just Remdesivir, no repurposed drug or combination including Hydroxychloroquine <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">reduced </a>chances of death of a COVID-19 patient, according to the <keyword id="808941" type="PERSON" weightage="20" keywordseo="WHO-study">WHO study</keyword>. </li></ul>Remdesivir, one of the earliest touted treatments for COVID-19 in the world, is not effective in preventing deaths of coronavirus patients, according to a study sponsored by the World Health Organisation study. The results of the study — <a href="https://www.ft.com/content/ee9b611f-2b4b-4572-afe1-b0b804d17a94">covering</a> over 2,700 people for Remdesivir across 30 countries — were posted online on October 15 and are not peer-reviewed yet. The researchers tried to treat a patient with Remdesivir for 10 days, where each patient received a 200 milligrams (mg) dose on the first day and 100 mg doses on subsequent days. “These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay,” noted the findings of the WHO’s Solidarity trial that was released on medRxiv. Gildead disagrees with WHO study Remdesivir was originally developed by Gilead Sciences to treat the Ebola virus and Hepatitis C. The company has so far <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">refuted</a> all the claims made by the WHO study. It asserts that more rigorous studies have found Remdesivir beneficial. “The emerging data appear inconsistent with more robust evidence from multiple randomised, controlled studies validating the clinical benefit of (Remdesivir),” Gilead <a href="https://www.ft.com/content/ee9b611f-2b4b-4572-afe1-b0b804d17a94">said </a>in a comment. WHO has not made in public comment since the study is not public yet. Not just Remdesivir, no repurposed drug or combination including Hydroxychloroquine <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">reduced </a>chances of death of a COVID-19 patient, according to the WHO study. WHO study brings bad tidings for Remdesivir producers Remdesivir is currently the only antiviral drug <a href="https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html">authorised </a>for treating COVID-19 in the US. It was taken by <a href="https://www.businessinsider.in/politics/world/news/trump-baselessly-says-he-may-be-immune-to-covid-19-after-being-hospitalized-and-treated-with-a-steroid-used-for-severe-cases/articleshow/78505594.cms">US President Donald Trump </a>when he was admitted to the hospital after testing positive for the virus. India’s Health Ministry too approved the use of the drug to treat mild cases of coronavirus. However, the drug is not recommended to treat those who have several renal impairments, pregnant and lactating women, children below 12 years age. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td colspan="3" style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cost of Remdesivir treatment in India </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cost of Therapy </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹32,400 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹24,000 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jubilant Lifesciences </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">JUBI-R </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹28,200 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cadila Healthcare </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹16,800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Mylan </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Desrem </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹28,800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy’s </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Redyx </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹32,400 </td></tr></tbody></table>Source:Nomura report dated October, 2020. There are six pharmaceutical giants in India — including Hetero Labs, Jubilant Lifesciences, Dr. Reddy’s Laboratories, Biocon firm Syngene and Zydus Cadila Healthcare — who have signed a non-exclusive agreement with Gilead to produce Remdesivir. The WHO study is likely to be a setback for all the pharmaceutical companies producing Remdesivir. The increasing number of cases in India drove the demand for Remdesivir. According to industry experts, Remdesivir was bringing in at least ₹6.5 million to ₹13 million in revenues per day at the current caseload. “Assuming 5% to 10% market share, we estimate current demand at 1,200 to 2,400 vials per day, which translates to ₹6.5 million to ₹ 13 million in revenues per day at the current caseload. We factor in ₹1.2 billion and ₹0.9 billion in sales from Remdesivir in FY21F and FY22F respectively,” a Nomura report dated October 2020 said. WHO isn’t alone in its skepticism of Gilead’s Remdesivir Remdesivir emerged as one of the most preferred treatments for COVID-19 — this new found disease that was threatening the world — largely driven by Gilead’s narrative. Even before WHO’s study, a Lancet report <a href="https://www.businessinsider.in/science/health/news/remdesivir-the-coronavirus-miracle-drug-may-be-overhyped-suggests-lancet-study/articleshow/75470476.cms">contradicted</a> the pharmaceutical giant’s claims indicating that Remedesivir may not be the most ‘promising’ treatment for coronavirus. It warned that Remdesivir provided no clinical benefits to patients who have tested for coronavirus. Despite the warnings, Gilead Sciences continue to claim Remdesivir as a plausible treatment for COVID-19. In July, Gilead released further data suggesting that it <a href="https://www.ft.com/content/978b4f8a-62b5-43a0-ad32-dda1930ec47c">may improve chances of survival. </a>However, these findings have not been confirmed by a randomised controlled trial until now. “What all of us would like to see is what is frequently called a ‘magic bullet’; a drug that’s already in existence, that is safe and works effectively in patients. Unfortunately, in this case, this trial at least suggests the benefits of Remdesivir weren’t there at all,” Julie Fischer, an associate research professor in the Department of Microbiology and Immunology at Georgetown University <a href="https://www.aljazeera.com/news/2020/10/16/who-trial-finds-repurposed-drugs-have-little-effect-on-covid-19">told Al Jazeera</a>. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/chinas-covid-19-coronavirus-is-safe-prompts-antibody-response-says-a-lancet-study/articleshow/78696495.cms">China's COVID-19 coronavirus is safe, prompts antibody response, says Lancet </a>

Remdesivir drug fails to reduce mortality or hospital stay of COVID-19 patients, says WHO study

<ul><li>The <keyword id="6354458" type="UNKNOWN" weightage="20" keywordseo="US">US</keyword> Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September.</li><li>This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials.</li></ul> The Donald Trump administration has secured nearly the entire world stock of antiviral drug <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">remdesivir</keyword> from US-based Gilead Sciences for the next three months, leaving hardly any stock of the key Covid-19 drug for the rest of the world. As a result of an agreement with the drug maker announced earlier this week, the US Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September. This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials. A treatment course of remdesivir is, on average, 6.25 vials, the US Health and Human Services said. The agreement allows hospitals in the US to purchase the drug in amounts allocated by HHS and state health departments. Hospitals in the US will receive the product shipped by AmerisourceBergen and will pay no more than Gilead's Wholesale Acquisition Price (WAC), which amounts to approximately $3,200 per treatment course. "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19," US Health and Human Services Secretary Alex Azar said in a statement. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people." Remdesivir is considered a key drug in the fight against Covid-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. To expand supply of remdesivir, Gilead earlier announced non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in India, Egypt and Pakistan The agreements allow the companies -- Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences; Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. -- to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access. The regulatory approval status of remdesivir varies by country, and the distribution of remdesivir within each country is subject to local laws and regulations. Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding Covid-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier.

You Searched For "Zydus Lifesciences" and got 10 results

Zydus Q4 net profit surges 4-fold to ₹1,182 cr; revenue at ₹5,534 cr

PTI

Zydus Lifesciences acquires UK-based LiqMeds Group for GBP 68 million

PTI

Zydus Lifesciences Q1 2023-24 profit up 2-fold at Rs 1,087 cr

PTI

Cadila Healthcare trumps peers, in talks to acquire Claris Lifesciences for whooping Rs 3,400 crore

BI India Bureau

These are the companies that are making Remdesivir in India

BI India Bureau

These are the companies that are making Remdesivir in India

BI India Bureau

Cipla to sell anti-viral drug remdesivir as Cipremi in India

IANS

US outlook improves for Indian pharma but domestic market under the cloud

Katya Naidu

Remdesivir drug fails to reduce mortality or hospital stay of COVID-19 patients, says WHO study

Preeti Soni

US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months

IANS

Popular Keywords

Buying Guides